Status:
COMPLETED
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Breast Cancer
Leukemia, Myeloid, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.
Eligibility Criteria
Inclusion
- Inclusion criteria (for both study populations):
- Men or women of nonchildbearing potential (WONCBP) aged 18 to 65 years inclusive at screening.
- WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for more than 1 year (with follicle-stimulating hormone \[FSH\] level greater than or equal to 8 mIU/mL) and must have a negative serum pregnancy test result within 48 hours before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound scan. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue using it for 12 weeks after test article administration.
- Have a high probability for compliance with and completion of the study.
- Exclusion criteria (for both study populations):
- History of clinically important cardiovascular disease.
- Family history of QT prolongation, syncope, seizure, or unexplained cardiac-related death.
- Presence or history of any disorder that may prevent the successful completion of the study.
- Other inclusion and exclusion criteria apply.
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00759837
Start Date
October 1 2008
End Date
May 1 2009
Last Update
July 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Warsaw, Poland, 02-507